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Background
Clinical trials with the newer 2nd generation antihista-
mines in children under the age of 12 years have been
performed previously but further studies are needed in
order to show efficacy and safety in the most unfavour-
able clinical conditions such as persistent allergic rhinitis
(PER). Rupatadine oral solution was developed for chil-
dren with allergic rhinitis in view of its rapid onset of
action and its lack of relevant side effects. These advan-
tages were confirmed previously in a phase III study in
children 6-11 years.
Objective
To assess the efficacy and safety of rupatadine (RUP)
oral solution in a subgroup of children between 6 and
11 years weighing ≥25 kg with PER.
Methods
A subanalysis was performed from a previous placebo-
controlled study carried out in patients between 6-11
years diagnosed as PER according to ARIA criteria.
This analysis included patients with a positive prick
test, weight ≥25 kg and basal nasal symptoms score
(including rhinorrhea, nasal blockage, sneezing and
nasal itching assessment) ≥24 obtained in 4 days
throughout the 2-week screening period. Patients were
allocated to treatment with either RUP oral solution
(1 mg/ml) or placebo during 6 weeks. The dose was
5 ml of oral solution. The main efficacy endpoint was
the change from baseline of the nasal (4TSS) and glo-
bal symptoms (5TSS) score at 4 and 6 weeks of treat-
ment. Furthermore the assessment of children’s quality
of life at 4, 6 weeks by means of PRQLQ was also
evaluated.
Results
The subgroup analysed was a total of 266 randomized to
rupatadine (n=131) or placebo (n=135). Table 1 sum-
marizes the efficacy results:
Conclusion
Rupatadine oral solution (1mg/ml) was significantly
more effective than placebo in improving nasal symp-
toms (4TSS) at 4 and 6 weeks. This is the first clinical
evidence of a H1-receptor antagonist efficacy in children
between 6-11 years over 25 kg with PER.
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Table 1
Mean score reduction Placebo (n=135) Rupatadine (n= 131) P-value
4TSS at 4 weeks -2.4 (1.9) -3.1 (2.1) P < 0.01
4TSS at 6 weeks -2.6( 2.0) -3.4 (2.1) P < 0.01
5TSS at 4 weeks -2.7 (2.4) -3.7 (2.5) P < 0.01
5TSS at 6 weeks -2.9 ( 2.5) -4.0 (2.6) P < 0.01
PRQLQ overall score showed statistical significant differences between RUP
and placebo at 4 weeks (p=0.01) and 6 weeks (p<0.05). Adverse events were
scarce in both treatment groups throughout the study. Somnolence was
reported with a very low incidence (1.4% RUP) and no serious adverse events
were reported.
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